Current Clinical Trials

Department: Oncology
Diagnosis: Oncology - General
Principal Investigator:
Sub-Investigator(s):
Sponsor: NCI
Details (Identifier #): NCT02502266
Title: Protocol NRG-GY005,A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: ECOG
Details (Identifier #): NCT01169337
Title: E3A06: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
Department: Cardiology
Diagnosis: Cardiac - Arrhythmia
Principal Investigator: Deshmukh MD, Pramod
Sponsor: St. Jude Medical
Details (Identifier #): NCT02548455
Title: A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an Investigational Device Exemption (IDE) Study
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Details (Identifier #): NCT02224781
Title: EA6134, A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Department: Gastroenterology
Diagnosis: Gastrointestinal - Crohn's
Principal Investigator: Georgetson MD, FACG, Michael
Sponsor: Salix
Details (Identifier #): NCT02240121
Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional Study to Assess the Efficacy and Safety of Rifaximin Delayed Release Tablets for the Induction and Maintenance of Remission in Subjects with Active Moderate Crohn's Disease (RECD3125)
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Details (Identifier #): NCT02339571
Title: EA6141, Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Department: Oncology
Diagnosis: Gastrointestinal - Pancreas
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Details (Identifier #): NCT01013649
Title: RTOG0848, A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
Department: Cardiology
Diagnosis: Cardiac - Congestive Heart Failure
Principal Investigator: Deshmukh MD, Pramod
Sponsor: Impulse
Details (Identifier #): NCT01381172
Title: Evaluation of the Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure With Ejection Fraction Between 25% and 45%: FIX-HF-5C
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: RTOG
Details (Identifier #): NCT01822496
Title: RTOG 1306, A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: Golden Biotech
Details (Identifier #): NCT02047344
Title: GHNSCLC-2-001, A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients with Stage IV (including Pleural Effusion) Non-Squamous Non-Small Cell Lung Cancer (NSCLC) who have Failed Two Lines of Anti-Cancer Therapy